Strength
200 mg/1
Manufacturer
Salix Pharmaceuticals Inc.NDC
65649030103
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Last Updated
1/1/2025
Active Ingredients
RIFAXIMINApproval Type
New Drug (NDA)
FDA Application
NDA021361On Market Since
7/25/2004
Pharmacological Classes
Rifamycin Antibacterial
Rifamycins
Generic Alternatives
No alternatives available
No alternatives found with the same active ingredient, strength, and dosage form.